News from the FDA: the indication for a drug targeting EGFR is expanded to uncommon mutations

[MFH_Advocate]

The FDA has expanded the indication for afatinib (Gilotrif) to include the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have uncommon EGFR alterations in L861Q, G719X, and/or S768I. onclive.com/web-exclusives/... This FDA approval was based on trials studying the response to afatinib in patients whose tumors had mutations in EGFR. The results help advance our understanding of the efficacy of afatinib and also highlight the importance of tumor testing of patients with lung cancer.

[scifiknitter Blogger]

More options are good news! This is based on a small subset of patients, but response rates and duration of efficacy were're both compelling.